Hemogenyx Pharmaceuticals PLC (HEMO)

Currency in GBP
775.000
0.000(0.00%)
Closed·
HEMO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
731.157820.000
52 wk Range
124.5001,790.000
Key Statistics
Bid/Ask
730.00 / 849.00
Prev. Close
775
Open
775
Day's Range
731.157-820
52 wk Range
124.5-1,790
Volume
419
Average Volume (3m)
20.63K
1-Year Change
405.7096%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HEMO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock price movements are quite volatile
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Apr 30, 2026
EPS / Forecast
-0.89 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

HEMO Income Statement

Compare HEMO to Peers and Sector

Metrics to compare
HEMO
Peers
Sector
Relationship
P/E Ratio
−5.6x−6.7x−0.4x
PEG Ratio
0.19−0.220.00
Price/Book
46.0x1.6x2.6x
Price / LTM Sales
-14.0x3.0x
Upside (Analyst Target)
-176.2%51.9%
Fair Value Upside
Unlock−13.0%9.4%Unlock

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. The company also treats for solid and rare cancers; and immune system and autoimmune diseases. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
12.78K0.19%99.02K
Other Institutional Investors
4.09M60.17%31.71M
Public Companies & Retail Investors
2.70M39.64%20.89M
Total
6.8M100.00%52.7M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Hargreaves Lansdown Asset Management Ltd.20.21%1,374,36910,651
Aberdeen Group Plc10.35%703,5445,452

People Also Watch

3.000
GWMO
-1.64%
70.50
AVCT
+1.44%
0.0180
PREM
+5.88%
151.92
SPCX
+2.44%
2.48
EUA
0.00%

FAQ

What Is the Hemogenyx Pharma (HEMO) Stock Price Today?

The Hemogenyx Pharma stock price today is 775.000 GBP.

What Stock Exchange Does Hemogenyx Pharma Trade On?

Hemogenyx Pharma is listed and trades on the London Stock Exchange.

What Is the Stock Symbol for Hemogenyx Pharma?

The stock symbol for Hemogenyx Pharma is "HEMO."

What Is the Hemogenyx Pharma Market Cap?

As of today, Hemogenyx Pharma market cap is 55.010M GBP.

What Is Hemogenyx Pharma's Earnings Per Share (TTM)?

The Hemogenyx Pharma EPS (TTM) is -2.197.

From a Technical Analysis Perspective, Is HEMO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Hemogenyx Pharma Stock Split?

Hemogenyx Pharma has split 1 times.

How Many Employees Does Hemogenyx Pharma Have?

Hemogenyx Pharma has 16 employees.

What is the current trading status of Hemogenyx Pharma (HEMO)?

As of Jul 09, 2026, Hemogenyx Pharma (HEMO) is trading at a price of 775.000 GBP, with a previous close of 775.000 GBP. The stock has fluctuated within a day range of 731.157 GBP to 820.000 GBP, while its 52-week range spans from 124.500 GBP to 1,790.000 GBP.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.